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Background: The use of in vitro cell cultures is a powerful tool for obtaining key
insights into the behaviour and response of cells to interventions in normal and dis-
ease situations. Unlike in vivo settings, in vitro experiments allow a fine‐tuned control
of a range of microenvironmental elements independently within an isolated setting.
The recent expansion in the use of three‐dimensional (3D) in vitro assays has created
a number of representative tools to study cell behaviour in a more physiologically 3D
relevant microenvironment. Complex 3D in vitro models that can recapitulate human
tissue biology are essential for understanding the pathophysiology of disease.
Aim: The development of the 3D coculture collagen contraction and invasion assay,
the “organotypic assay,” has been widely adopted as a powerful approach to bridge
the gap between standard two‐dimensional tissue culture and in vivo mouse models.
In the cancer setting, these assays can then be used to dissect how stromal cells, such
as cancer‐associated fibroblasts (CAFs), drive extracellular matrix (ECM) remodelling
to alter cancer cell behaviour and response to intervention. However, to date, many
of the published organotypic protocols are low‐throughput, time‐consuming (up to
several weeks), and work‐intensive with often limited scalability. Our aim was to
develop a fast, high‐throughput, scalable 3D organotypic assay for use in oncology
screening and drug development.
Methods and results: Here, we describe a modified 96‐well organotypic assay, the
“Mini‐Organo,” which can be easily completed within 5 days. We demonstrate its
application in a wide range of mouse and human cancer biology approaches including
evaluation of stromal cell 3D ECM remodelling, 3D cancer cell invasion, and the
assessment of efficacy of potential anticancer therapeutic targets. Furthermore, the- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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Conclusions: The Mini‐Organo high‐throughput 3D organotypic assay allows the
rapid screening of potential cancer therapeutics in human and mouse models in a
time‐efficient manner.
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Mammalian tissues are highly complex microenvironments where a
close interplay exists between the cellular and acellular compart-
ments.1-4 This complex and reciprocal interaction is technically chal-
lenging to reproduce in vitro as both healthy and diseased tissues
co‐evolve over time. Furthermore, in vivo study of these complex tis-
sue environments is time‐consuming and labour intensive, and exper-
imental manipulation is typically limited.5,6
Two‐dimensional (2D) in vitro culture models represent the main-
stay of the majority of cell biology. Whilst these models have resulted
in the vast knowledge accumulated over the past decades, it is now
becoming increasingly apparent that data generated in these models
typically do not extrapolate to the three‐dimensional (3D) setting.5
There are several reasons for this: 2D plastic surfaces are much stiffer
in comparison to most tissues except bone and so do not capture the
biomechanics of native tissue environments; 2D tissue culture also
lacks the complex heterogeneous 3D nature of the Extracellular matrix
(ECM), where extrinsic cues and clues are presented on nanoscopic,
microscopic, and macroscopic scales to cells. Cell behaviour and phe-
notype are the complex integration of collective nonlinear interactions
between cellular and environmental cues.7 Cells within 3D environ-
ments continually assimilate and process the information received
leading to alterations in their intracellular signalling that governs cell
fate.8 2D culture therefore cannot replicate crucial spatial compart-
mentalization of extrinsic signalling cues which constitutes a funda-
mental feature of the 3D ECM landscape and underpins the very
essence of tissue and organ complexity.9
As a result, in the last few decades, there has been an explosion in
the emergence of novel approaches to produce more physiologically
relevant and tuneable 3D cultures, increasing not only the fidelity of
these models, but also dramatically improving our ability to monitor
and image cellular response enabling real‐time study.5,10-14 Within
these models, genetic, epigenetic, immunological, and chemical pertur-
bation of malignant and nonmalignant cells and tissues can be tested
against carefully controlled microenvironmental factors such as oxygen
tension, pH, reactive oxygen species, growth factors as well as ECM
biochemistry and biomechanics. These approaches are slowly bridging
the gap between complex in vivo experiments and in vitro experiments.
They allow us to answer not only key biological questions, but more
importantly in disease models, it allows us to rapidly and reliably screenand test novel therapeutic approaches to increase the fidelity of pre-
clinical portfolios. One caveat, however, is that many of these 3D
in vitro model systems are time‐consuming and work‐intensive with
often limited scalability. Thus, the miniaturisation and integration of
organotypic culture models into high‐throughput assays can lead to
the rapid evaluation of novel drugs in a cost‐effective and time‐
effective manner.15-18 From a clinical perspective, a cost‐efficient pro-
tocol to validate drug efficacy in ex vivo patient‐derived transplants
could facilitate personalised decision making in oncology.19-21
Extracellular matrix deposition, contraction, and remodelling are
common to diseases such as tissue fibrosis, diabetes, and tissue aging
and importantly are salient features of almost all solid tumours.3,22 Prior
to and duringmalignant transformation and tumour expansion, the host
stroma typically initiates a desmoplastic stromal response.1,23-26 This
response leads to a significant deposition and remodelling of the ECM
within and surrounding the tumour. Whilst still the topic of much
debate as to the precise antitumourigenic and/or protumourigenic
properties of this fibrotic reaction, it ultimately leads to a significantly
altered tumour microenvironment both biochemically and biomechani-
cally.27-31 The response is manifested by the presence of activated
fibroblasts, either resident or recruited to the site of the developing
tumour.1,2,32-38 These fibroblasts have been shown to be the major
source of tumour desmoplasia, by secreting and remodelling ECM com-
ponents including collagens. These cancer‐associated fibroblasts
(CAFs) are now seen as critical in the progression of many solid
tumours.2,25,32,37,39-41 Thus, given the critical importance of these stro-
mal cells in tumour onset and progression, their inclusion in 3D cancer
models is of utmost importance.
Here, we describe a modified organotypic assay, the “Mini‐
Organo,” that adapts and improves previously published proto-
cols10,42-44 by significantly reducing the time for contraction and inva-
sion to occur, so that it can be quickly scaled for large‐scale drug
testing and completed within 5 days. We demonstrate its application
in a wide range of mouse and human cancer biology approaches
including evaluation of stromal cell (CAF) 3D ECM remodelling, 3D
cancer cell (CC) invasion, and the assessment of potential anticancer
therapeutic targets. Furthermore, the Mini‐Organo assay described is
highly amenable to customisation using different cell types under
diverse experimental conditions and so can easily be adopted to
noncancer studies. An overview of the workflow for the Mini‐Organo
is shown in Figure 1.
FIGURE 1 Schematic of workflow. A, Collagen extraction and preparation from rat tails for use in the Mini‐Organo. B, BSA coating of microwell
plates to facilitate contraction of Mini‐Organos. C, Preparation of cells for seeding. D, Preparation of Mini‐Organo stock solution. E, Plating out of
Mini‐Organos. F, Polymerisation of Mini‐Organos prior to contraction. G, Fibroblast‐driven remodelling and contraction phase. H, Transfer to air‐
liquid interface and cancer cell seeding and invasion phase. I, Automated scoring
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REQUIRED AND REAGENT SETUP
2.1 | Preparation of native acid‐extracted collagen
source (yields approx. 1 g of purified Collagen I)
This step details the in‐house extraction and preparation of large
batches of high quality Collagen type I (hereafter “collagen I”) for
use in the Mini‐Organos. It is not necessary to extract fresh collagen
I for every experiment, and batches of extracted collagen can be
sterilised and stored at 4°C for several months. If a suitable collagen
I source is in place, steps 2a and 3a can be omitted. The “5‐day”
Mini‐Organo does not include the generation of a stock collagen
solution; however, for completeness, we have included this step.
Here, we describe a protocol for extracting collagen I from rat tails,although other alternative methodologies and sources may be
used.10,42,45
• 12 to 14 tails from rats of any age and/or strain.
• Sterile (autoclaved) acetic acid solutions at 0.5 M (2 L), 0.25 M
(0.5 L), and 17.4mM (~40 L) concentrations.
• Filter paper (Chux, Whattman, or coffee filters—any sturdy filter
paper for filtering out insoluble tail sheath).
• Cooled centrifuge with ~200‐mL capacity buckets.
• Toothed forceps.
• Scalpels (no. 22.)
• Dialysis tubing 14 000 MWCO
• Sodium chloride (NaCl) salt.
4 of 15 CHITTY ET AL.• Collagen quantification kit, Sircol assay (Biocolor Ltd. Cat #S1111),
or similar.
2.2 | Cell culture
• Fibroblasts of interest, ie, cancer‐associated fibroblasts (CAFs)
including predetermined optimal growth medium and incubation
conditions. The choice of CAF used will affect the degree of con-
traction and also invasion. The number of CAFs and length of time
for contraction of the matrices will need to be optimised for each
CAF line used (described later).○ In this work, we demonstrate ECM remodelling using the fol-
lowing CAF lines.
“KPC CAFs” derived from the autochthonous mouse model of
the LSL‐KRasG12D/+, LSL‐Trp53R172H/+, Pdx1‐Cre (KPC) pan-
creatic ductal adenocarcinoma (PDAC).46
“KPflC CAFs” derived from the autochthonous mouse model
of the LSL‐KRasG12D/+, LSL‐Trp53fl/+, and Pdx1‐Cre (KPC)
PDAC.47
KPC CAFs are grown in Dulbecco's modified Eagle's medium
(DMEM) containing 10% fetal bovine serum, penicillin‐
streptomycin (10 000 U/mL penicillin G sodium and
10 000 μg/mL streptomycin sulphate). Cells are cultured at
37°C in a humidified incubator in atmospheric O2 supple-
mented with 5% CO2.
“KPC CCs” are derived from the autochthonous mouse model
of The LSL‐KRasG12D/+, LSL‐Trp53R172H/+, and Pdx1‐Cre
(KPC) PDAC.
KPC CCs are grown in DMEM containing 10% fetal bovine
serum and penicillin‐streptomycin (10 000 U/mL penicillin G
sodium and 10 000 μg/mL streptomycin sulphate). Cells are
cultured at 37°C in a humidified incubator in atmospheric O2
supplemented with 5% CO2.
“HN‐CAFs” are derived from a human head and neck carci-
noma, “V‐CAFs” are derived from a human vulval carcinoma,
and “Cer‐CAFs” are derived from a human cervical carcinoma.
All human CAFs (HN‐V‐ and Cer‐CAFs) were collected from
fresh patient tissue under approved ethical review and
immortalised using the hTERT lentivirus. Further information
and characterisation of these human CAFs have previously
been published.48-51
Human CAFs are grown in DMEM with high glucose, 10%
fetal bovine serum, and penicillin‐streptomycin (10 000 U/
mL penicillin G sodium and 10 000 μg/mL streptomycin sul-
phate) and supplemented with Gibco Insulin‐Transferrin‐
Selenium (1×) solution. Cells are cultured at 37°C in a humidi-
fied incubator in atmospheric O2 supplemented with 5% CO2.
All cell lines were regularly tested for mycoplasma and for
murine pathogens by IMPACT testing (IDEXX Laboratories,
Inc.).Reagents required
• 0.25%trypsin‐EDTA.• 1x phosphate buffered saline (PBS).
• Trypan blue for cell counting (0.4% stock solution).
• Cell strainers (100, 70, and 40 micron).2.3 | Collagen I Mini‐Organo preparation and
contraction
• 1% bovine serum albumin (BSA) in PBS.
• Prepared rat tail collagen I at a minimum concentration of 2.5 mg/
mL
• Fetal bovine serum (FBS)
• Collagen neutralisation buffer (CNB) made up of 0.5× minimal
essential medium (MEM), 0.1 M HEPES buffer (pH 7.5), 238 mM
NaHCO3.
• Fibroblast optimised growth medium (as determined in 2b).
• 25 and 50‐mL plastic reservoirs.
• 96‐well cell culture‐treated plates
• Wide, shallow ice tray for keeping plates cool during preparation of
Mini‐Organos2.4 | Collagen I Mini‐Organo invasion
• Stainless steel round screen mesh size 40 (sigma S0770). Each
mesh is cut six times at ~25‐mm intervals, to a depth of 10 mm.
This allows three arms to be bent down creating a platform approx-
imately 3 to 4 mm high (see Figure 1H)
• 60 × 15‐mm cell culture dish
• Sterile blunt forceps and/or micro spatula/spoon
(0.5 × 0.5 × 0.7 mm) for transferring mini‐organos
• Optimised growth medium.2.5 | Equipment needed
• 200‐μL and 1‐mL pipettes (incl. sterile tips).
• Benchtop centrifuge at room temperature.
• Cell counter (automated or haemocytometer).
• Standard tissue culture incubator suitable for cells of interest.
• Stepper pipette*.
• Multichannel pipette*.
• Charge‐coupled device (CCD) scanner capable of detecting a sam-
ple placed outside the ideal focal plane. Contact image sensor
(CIS) scanners are not suitable due to the shallow scan depths.
* With the large amount of pipetting and smaller working volumes
accompanying scaling of the Mini‐Organo, it is essential to use both a
stepper pipette and multichannel pipette for accurate repeated mea-
sures to improve accuracy and reduce variability.
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3.1 | Preparation and quantification of high quality
rat tail collagen
i. All work should be carried out using clean, sterile equipment. The
use of a laminar flow hood is strongly advised, although not essen-
tial. Wash 12 to 14 rail tails (to give a total of 75‐100 g of tails) in
70% ethanol, and leave to soak to soften the tails but do not leave
for longer than 30 minutes. To remove the collagen‐rich tendons,
rotate a scalpel blade around the proximal region of the tail, care-
fully cut the skin of the tail along its length, and peel away the skin
from the proximal cut (the skin should come off in one piece).
Using toothed forceps, grip midway between the largest section
of the tendon to maximise the tendon removed. Twist the tendon
slightly to improve the grip and remove the tendon from the upper
sheath, pulling towards the tip of the tail in a controlled movement.
Take care not to remove too much accompanying sheath in the
process. Once removed, collect the tendons into fresh MilliQ
water. A visual demonstration of the approach has been previously
published by Timpson and colleagues.42
ii. Solubilise the collagen I from the rat tail tendons by transferring
from MilliQ to 1500 mL of 0.5 M acetic acid for at least 48 hours
at 4°C. If after 48 hours large pieces of tendon are still visible, leave
for another 24 hours. Use a magnetic stirrer to ensure constant
mixing of the acetic acid and tendons. The solution should appear
slightly viscous.
Note: Prior to solubilisation, the harvested tendons can be briefly
snap frozen at −80°C for approximately 15 minutes. Once frozen, ten-
dons can then be ground in a mortar and pestle to increase surface
area and improve acetic acid dissolution of the collagen I in order to
increase yield.
iii. Once solubilised (>48 hours), filter the collagen extract through
wetted (in 0.5 M acetic acid) Whatman paper or equivalent filter
to remove any remaining sheath that was transferred with the ten-
don. The resulting collagen I rich solution should have a thick
consistency.
iv. Centrifuge the extracted collagen I solution at 10 000 rpm at 4°C
for 1 hour. Carefully decant the supernatant and discard the pellet.
v. Transfer the collagen solution (supernatant) (1.5 L) to a clean 2‐L
conical flask. Add NaCl salt to the supernatant to make a solution
with final concentration 10% w/v NaCl solution (eg, 150 g to
1500 mL). This will precipitate out the collagen I from solution
ready for collection.
Note: Be sure to add the NaCl crystals slowly, breaking up any
clumps until they have fully dissolved. Do this slowly over in three
to four intervals over a 30 to 60‐minute period with continuous stir-
ring. Once all NaCl has been added and dissolved, the solution should
be a homogenous, white‐opaque solution.vi. Centrifuge the solution at 10 000 rpm at 4°C for 30 minutes.
Carefully discard the supernatant.
vii. Re‐dissolve the precipitated collagen I pellet in 0.25 M sterile
(autoclaved) cold (4°C) acetic acid at an approximate 1:1 volume
ratio of acetic acid to precipitated collagen I for 24 hours at 4°C.
This volume may be adjusted to ensure that the collagen is
completely dissolved. Typically, 200 to 400 mL is required.
viii. Once re‐dissolved, dialyze the collagen solution against six to
eight changes of 5 L of sterile 17.4 mM acetic acid (5‐mL glacial
acetic acid [17.4 M] into 5 L of 4°C distilled water) for 3 to
4 days. Use a magnetic stirrer to increase dialysis efficiency.
The dialysis solution should be replaced twice daily (~8‐
12 hours between changes).
ix. Centrifuge the dialyzed collagen I at 14 000 rpm at 4°C for
1.5 hours to remove any insoluble matter. A small pellet may be
visible, but this should be minimal.
x. Carefully decant or aliquot the collagen I solution into sterile
containers.
xi. Collagen I concentration should be accurately determined using a
kit such as the Sircol collagen quantification kit (BioColor Ltd) or a
modified Lowry assay.52 With high concentrations of collagen, the
higher volume of standards should be used and collagen diluted
1:10 or 1:20 to be within range.
xii. Adjust the collagen I concentration to 2.5 mg/mL (or desired con-
centration) using 0.5 mM acetic acid at 4°C.
xiii. Using a biological safety cabinet or equivalent UV light source,
sterilise the collagen I solution for 20 minutes on ice before stor-
ing at 4°C. For long‐term storage, the solution should be lyoph-
ilized and stored at 4°C. Once this collagen stock is
established, it is ready for use in the Mini‐Organo.3.1.1 | Anticipated results
A starting amount of 75 to 100 g of rat tails (representing an average
of 12 rat tails weighing 6‐8 g each) should yield a final amount of
approximately 1.0 to 1.5 g of purified collagen I consisting a volume
of 500 mL at approximately 2.5 mg/mL collagen I. The extraction pro-
cedure above can be modified to yield higher concentrations of colla-
gen by either increasing number of rat tails used and also by increasing
the number of days dialysis (step 3a viii) is performed. However, after
4 days, the increase in yield is typically marginal. Alternatively, multiple
batch extractions can be performed and pooled to create a central
stock for large‐scale experiments. Contraction and/or invasion exper-
iments described later may be affected by the batch of collagen I used
and so it may be necessary to test each batch when working with mul-
tiple extractions over sustained periods of time.
It is important to keep the collagen I solution cold at all times to
avoid unwanted degradation and polymerisation. A collagen I solution
that is not translucent at stage viii will likely be of poor quality. Simi-
larly, a final stock concentration of below 2.5 mg/mL will not be
6 of 15 CHITTY ET AL.suitable for downstream applications described in this protocol.
Higher stock concentrations can be generated, up to 4 to 5 mg/mL
and may be necessary for some highly invasive CC lines (such as the
fibrosarcoma cell line HT1080) or highly contractile CAFs.
The above protocol should yield approximately 1.0 to 1.5 g of puri-
fied acid‐extracted collagen I which is enough to produce approxi-
mately 30 to 50 separate 96‐well plates, equivalent to 3000 to 5000
experimental conditions.3.2 | Preparation of Mini‐Organo hydrogels
i. Contraction of the collagen gels is facilitated by ensuring that the
gels are free from attachment to the 96‐well culture plate. To pre-
vent the Mini‐Organo gels sticking to the well, first coat the wells
with 1% BSA in sterile PBS for 1 hour in a tissue culture incubator
at 37°C (or at 4°C overnight) (Figure 1B). Once incubated, remove
the PBS/BSA solution and wash briefly with PBS twice before use.
BSA‐coated plates can be stored in PBS in the fridge for 24 to
48 hours.
ii. De‐gas the collagen I solution under vacuum for 15 minutes. This
step is important to prevent the formation of bubbles within the
Mini‐Organos.
iii. Trypinise fibroblasts/CAFs according to normal passage protocol
for your cell line (Figure 1C). Count the cells, resuspend in normal
growth medium at the required concentration, and keep on ice.
The precise cell number required per Mini‐Organo will need to
be optimised prior to experimental work (optimisation described
below in 3c. Anticipated Results).
iv. For 12 mL of collagen I Mini‐Organo mixture (enough for 1× 96‐
well plate at 100 μL per well, including pipetting dead volumes),
add the following components carefully and mix, taking care to
avoid bubbles (Figure 1D). Ensure that the following components
are kept on ice. Mix the reagents in a prechilled container on ice,
adding the collagen I solution as the last step. Once the collagen
I solution is neutralised, it will begin to gel unless kept at 4°C.
Due to the viscosity of the collagen I Mini‐Organo solution, it is
reasonable to expect to lose approximately 15% volume of the ini-
tial starting solution as dead volume during transfer to and from
reservoirs. This should be taken into consideration when scaling
up or down the protocol. If bubbles appear during the preparation
of the gel, a brief pulse centrifugation at 4°C should remove them.a. 0.96‐mL CNB
b. 1.20‐mL FBS (100%)
c. 2.64‐mL fibroblasts/CAFs in normal growth media (or just
normal growth media for acellular controls)
d. 7.2 mL of 2.5 mg/mL extracted collagen I solution (or equiv-
alent volume to yield a final concentration of 1.5 mg/mL col-
lagen I [or desired concentration])Note 1 . It is important to ensure correctneutralisation of the acid‐extracted collagen at thispoint. The MEM within the CNB contains phenol red,
and so the final gel solution should be pink/orange in
colour. A yellow colour implies a pH of close to 6.0
and that the collagen I solution has not been correctly
neutralised.
Note 2 . It is possible to mix in additional ECM com-
ponents to the Mini‐Organo mixture at this stage to
test effects on fibroblast contractile behaviour. For
example, the addition of ECM components such as
fibronectin may increase the contraction of some
fibroblast lines.v. Using the stepper pipette, add 100‐μL collagen I/cell hydrogel to
each well in a BSA‐coated 96‐well culture plate, taking care not
to introduce bubbles (Figure 1E). Tip: drawing up and emptying
the tip a couple of times will create a small dead volume (5‐
10 μL). This will allow a more precise volume to be transferred to
each well of the plate and, at the same time, avoid the formation
of bubbles during pipetting. Pipetting the collagen against the side
of the well and allowing it to run down into the well will also
reduce the likelihood of generating bubbles.
vi. Allow gels to polymerise for 1 hour in the incubator (37°C). Tomain-
tain consistent pore sizes across different experiments, it is essential
to ensure a standardised polymerisation protocol53-55 (Figure 1F).
vii. Once polymerised, wash the Mini‐Organos by adding 100‐μL
normal growth media for 1 hour in the incubator at 37°C.
viii. Carefully aspirate the growth medium using a multichannel
pipette (do not use vacuum aspiration).
ix. Add new growth media (+/− experimental interventions [growth
factors/drugs] and incubate at 37°C.
x. Monitor and/or image contraction of Mini‐Organos using a CCD
flatbed scanner capable of detecting a sample placed outside the
ideal focal plane. CIS flatbed scanners are not suitable due to the
shallow scan depths. The use of a flatbed scanner to image from
the bottom of the plate is preferred and gives more accurate deter-
mination of degree of contraction. Images can be taken as often as
necessary but should typically be carried out at least once every
24 hours.
xi. To obtain a quantitative measure for the level of Mini‐Organo con-
traction, the relative area of the well and the gel are measured
using ImageJ software (as depicted in Figure 2A,B). The percentage
of contraction is calculated using the following formula:
Contraction %ð Þ ¼ 100 × well area‐gel areað Þ
well area
:
3.2.1 | Anticipated results
The Mini‐Organos will set within 1 hour at 37°C at which time the gels
should go from clear to slightly opaque (Figure 1F). It is important to
FIGURE 2 Optimisation of the Mini‐Organo contraction assay. A, Schematic for remodelling and contraction phase including representative
images at 24‐hour, 48‐hour, and 72‐hour time points. B, Examples of scanned plates seeded with increasing numbers of KPC‐CAFs during
contraction and remodelling phase at 24, 48, and 72 hours (Dotted lines indicate gel circumference). C, Quantification of contraction over time for
different seeding densities of KPC‐CAFs. D, Quantification of final level of contraction at 72 hours is dependent on initial seeding cell number. E,
Quantification of final level of contraction at 72 hours is also dependent on starting concentration of collagen I. F, Total Picrosirius Red (PSR) signal
from remodelled Mini‐Organos increases as the degree of contraction increases. G, (Top) Picrosirius Red (PSR) polarised light analysis can be
employed to determine density and bundling of the remodelled collagen fibres, based on birefringent properties of dye bound collagen (Red—Thick
fibres; Green—thin fibres). (Bottom) Collagen fibre orientation analysis using second harmonic generation (SHG) two‐photon images can be used
to quantify changes in alignment of collagen fibres during contraction. H, Grey level co‐occurrence matrix (GLCM) analysis of second harmonic
generation (SHG) two‐photon images of collagen fibres can be used to map changes in fibre organisation and texture.
CHITTY ET AL. 7 of 15ensure that the Mini‐Organos, once set, are free from bubbles. The
best way to ensure this is to de‐gas the collagen I solution so that
the mixed solution is free from large bubbles. Also, avoid vigorous
pipetting because large bubbles will affect contraction and subsequent
invasion.
The small size of the Mini‐Organo matrices requires a high degree
of precision during casting as discrepancies will lead to variations in
the degree of contraction. A stepper pipette will improve the accuracy
of pipetting; however, a dead volume of 100 to 150 μL should be
taken into consideration.3.3 | Stromal cell remodelling of the ECM:
Mini‐Organo contraction assay
The first time a fibroblast/CAF line is used in the Mini‐Organo, it is
essential to standardise the number of cells seeded within each hydro-
gel. During all optimisations, control plugs with 0 cells are necessary as
a baseline for normalisation.
Once normal growth media (+/− experimental interventions
[growth factors/drugs]) have been added (step 2b ix), the plates can
be incubated 37°C in the requisite tissue culture incubator. Media
8 of 15 CHITTY ET AL.should be changed as needed. Plugs with high numbers of cells may
require media changes more frequently.
It is important to determine an optimal fibroblast/CAF seeding
density that allows reproducible determination of the remodelling of
the Mini‐Organos and for subsequent downstream invasion assays.
This will depend on three factors: (a) initial cell seeding number, (b)
length of time allowed to contract, and (c) initial starting concentration
of collagen I within the plug. For short‐term experiments, such as drug
screens, we recommend a scenario where the gels have contracted
30% by 72 hours. To begin with, serial dilutions of fibroblast/CAF
number should be used. Because the same plate can be imaged
repeatedly over several days, it is possible to determine both initial
seeding number and optimal contraction time in a single experiment.
In the example illustrated in Figure 2B,C, we show the effect of
changing KPC‐CAF number and incubation time on levels of contrac-
tion over 72 hours. As would be expected, higher numbers of CAFs
seeded within the Mini‐Organos lead to a greater rate of contraction,
which continues over the 72‐hour incubation period. Typically,
depending on cell number seeded, the maximal rate of hydrogel con-
traction occurs within the first 72 hours, after which the rate of con-
traction will slow and ultimately plateau.
3.3.1 | Anticipated results
The contraction of the fibroblast embedded collagen I plugs should be
visible by 24 hours at 37°C after generating the matrices. The degree
of contraction will be highly dependent on the initial concentration of
CAFs seeded to the matrix (Figure 2B‐2D), and also the activation sta-
tus of the fibroblasts/CAFs being used, as well as interventions being
applied. Furthermore, the initial starting concentration of collagen will
also alter the level of contraction seen at different time points
(Figure 2E). This combination of factors will ultimately determine the
resulting porosity of the final contracted Mini‐Organo, and as a result
the ability of CCs to invade.53
If using a fibroblast/CAF line for the first time, an assessment of
contractile behaviour should be undertaken and contraction curves
generated (Figure 2C). This will allow determination of optimal seeding
density to reach an approximate 30% to 50% contraction of the plugs
prior to seeding of CCs. Typically, no significant additional contraction
of the matrix is seen once the gels are transferred to the stainless steel
grids at the air‐liquid interface (Section 3d: Mini‐Organo Invasion
Assay).
Analysis of the extent of remodelling by embedded CAFs can be
undertaken at this stage. For example, Picrosirius Red staining is a sim-
ple and effective way to determine collagen density within the plugs
(Figure 2F). The specific staining of collagens by Picrosirius red is
one of the most important stains to study collagen networks.56,57 This
approach also has the added advantage that under polarised light, the
dye bound collagen fibre bundles appear green, red, or yellow and are
easily differentiated from the black background (Figure 2G [top]). This
allows for a quantitative morphometric analysis of the collagen fibres
where the polarised colours reflect fibre thickness and packing
(Figure 2G [top]). This approach has been applied by us and manyother groups to look at collagen fibre remodelling in organotypic stud-
ies as well as in normal and diseased tissues.10,58,59 Finally, second
harmonic generation (SHG) imaging is a label‐free imaging technique
that allows imaging of noncentrosymmetric entities such as collagen
fibres. The generation of an SHG signal occurs when two photons
with the same wavelength fuse into a single photon with half of the
original wavelength upon interaction with a non‐centrosymmetric
entity. This approach allows for high resolution imaging of collagen
fibres. Using SHG‐generated images, orientation of collagen fibres
can be assessed (Figure 2G [bottom]).10,58-61 In addition, collagen fibre
network organization can also be characterised using grey‐level co‐
occurrence matrix (GLCM) analysis.10,58,59,61-63 This method provides
a readout of the texture of a sample by quantifying the similarity
between pixels across an image64 (Figure 2H, data example shown is
from blebbistatin treated CAFs [Figure 4B]).
3.4 | 3D cancer cell invasion: Mini‐Organo invasion
assay
Following contraction, it is then possible to use the Mini‐Organos as
a physiologically relevant 3D assay to measure CC local invasion into
the remodelled collagen I rich interstitial matrix. The protocol
involves seeding a known number of CCs to the top of the Mini‐
Organo placed at an air‐liquid interface (Figure 1H). If desired, it is
possible to seed CCs on top of the gels immediately after polymeri-
sation and washing (prior to contraction). This allows a simultaneous
CAF‐CC 3D system to be exploited (simultaneous
contraction/invasion) but requires a growth medium compatible with
both cell types. Furthermore, it is also possible to kill the CAFs within
the contracted Mini‐Organo prior to the addition of the CCs. The
CAFs can be killed using either puromycin or detergent extrac-
tion48,65 followed by extensive washing.
i. Prepare CCs according to standard passaging protocol to yield a cell
suspension at a desired concentration. This will need to be deter-
mined in preliminary experiments. As a guide, cell numbers within
the range 1 × 103 to 5 × 104 CCs per Mini‐Organo are a good
starting point. Initially, seeding more CCs does not increase the
absolute number of cells invading into the Mini‐Organo (Figure 3F).
Note: It is important to ensure that a 0 CAF control is used in
experiments to determine the intrinsic capacity of tumour cells to
invade independently of CAFs (discussed later).
ii. Carefully remove media from contracted Mini‐Organos using a
pipette. Avoid using a suction pump. Add 100 μL of CC suspension
containing the desired number of cells.
Note: It is important to ensure an even distribution of the cell solu-
tion across the surface of the Mini‐Organo.
iii. Incubate for 12 to 24 hours under standard tissue culture condi-
tions to allow cells to adhere to the contracted Mini‐Organo.
FIGURE 3 Cancer cell invasion assay. A, Schematic overview of QuPath‐based scoring system. The number of cells which have invaded into the
gel is calculated as an index of the total number of cells seeded to the top of the gel. B, Increasing the number of CAFs seeded to the Mini‐Organo
during the contraction phase leads to an increase in the invasion of KPC cancer cells into the Mini‐Organo at the same timepoint. C, In addition to
simple haematoxylin and eosin staining (see panel B), it is possible to use immunohistochemical staining for markers of interest such as for pan‐
cytokeratin (which specifically stains the epithelial tumour cells) with data recapitulating that seen in H&Es. D, The effect of chemoattractants
(such as FBS) added to the media can be determined using the Mini‐Organo. E, Some (not all) cancer cell lines will invade more readily to a thin
layer of 1.5 mg/mL collagen I overlaid on top following transfer to the grids (+ col vs − col). KPC‐CCs invade regardless of the presence of this
additional top layer. F, Increasing the number of cancer cells seeded on top of the plug does not increase the absolute number of cancer cells
invaded into the plug; however, it will decrease the invasive index accordingly (see formula in Figure 3A). G, Therapeutic targeting of cancer cell
invasion can also be tested in Mini‐Organos. Treatment of KPC‐CCs with the non‐muscle Myosin II inhibitor Blebbistatin during the invasion stage
(drug not present during contraction phase) and shows significant decreases in cancer cell ability to invade into the remodelled Mini‐Organos. H,
Evaluation of the effects of anticancer therapies on invaded cancer cells can also be tested. Treatment of KPC‐CC with standard‐of‐care
gemcitabine leads to an increase in Cleaved Caspase3 (CC3)(Apoptosis). I, decrease in Ki67 (proliferation) as measured by IHC staining
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or six‐well plate.
v. Using sterilised blunt forceps, carefully transfer the Mini‐Organos
from the 96wp onto the top of the stainless steel grids (Figure 1
H). Multiple Mini‐Organos that are to be treated under the same
conditions can be placed onto the same grid. For each separate
treatment conditions, a separate dish and grid is required
(Figure 1H).vi. Once transferred, add complete growth media to the bottom of
the dish until it just covers the base of the Mini‐Organos. The
growth medium can be changed every day and will act as a
chemoattractant. This growth media can also contain
drugs/inhibitors/activators of interest (Figure 1H).
Optional step: TheMini‐Organos should sit at the air‐liquid interface
with the top layer of CCs exposed to the air. In some studies, this may
FIGURE 4 Targeting CAFs and stromal remodelling. A, Cancer associated fibroblasts derived from two matched models, the tumourigenic and
highly invasive KPC (KPC‐CAFs), and the tumourigenic but poorly invasive KPflC (KPCfl‐CAFs) models of pancreatic ductal adenocarcinoma
show differences in their ability to remodel the Mini‐Organos [2.5 mg/mL Col I] reflecting the differing aggressiveness of these two models. B,
Treatment of KPC‐CAFs (100 000 per Mini‐Organo [2.5 mg/mL Col I]) with the nonmuscle Myosin II inhibitor Blebbistatin shows a dose‐
dependent inhibition of the ability of KPC‐CAFs to remodel and contract the Mini‐Organos. C, Treatment of KPC‐CAFs (100 000 per Mini‐Organo
[2.5 mg/mL Col I]) with Blebbistatin; the ROCK inhibitor Fasudil or the PHD inhibitor DMOG (which mimics hypoxia) leads to a significant
reduction in the contraction of the Mini‐Organos. D‐F, Treatment of (D) human HN‐CAFs (70 000 per Mini‐Organo [3.5 mg/mL Col I + 20%
Matrigel]), (E) human V‐CAFs (50 000 per Mini‐Organo [3.5 mg/mL Col I + 20% Matrigel]), and (F) human Cer‐CAFs (50 000 per Mini‐Organo
[3.5 mg/mL Col I + 20% Matrigel]) with inhibitors of intracellular force generation (10‐μM Y‐27632, 10‐μM Blebbistatin, 10‐μM Mevastatin, or
10‐μM Verteporfin) show differential effects between the different tumour derived CAFs. G, Treatment of human HN‐CAFS (50 000 per Mini‐
Organo [3.5 mg/mL Col I + 20% Matrigel]) and human V‐CAF (40 000 per Mini‐Organo [3.5 mg/mL Col I + 20% Matrigel]) with 2 ng/mL
exogenousTGFβ leads to activation and increased contraction. H‐I, Exposure to hypoxia decreases CAF activation leading to a reduced contractile
ability, which can be rescued by the addition of exogenous TGFβ in both lines.
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CCs can be coveredwith an additional thin layer of collagen I (Figure 3E),
to avoid direct air contact. This may not be necessary for all cell lines.
vii. The time taken for invasion will depend on the aggressiveness
of the CC line in question and should ideally be within 72 hours.This can be optimised by varying the starting concentration of
collagen I, the degree of contraction by CAFs, the number of
CCs seeded, and the concentration of chemoattractant and/or
inhibitors used (see examples in Figure 3). As mentioned above
and discussed below, a 0 CAF control should be incorporated
into each experiment.
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During the invasion step, the CCs should invade into the remodelled
collagen I plug along the chemotactic gradient established by placing
the Mini‐Organo on top of the grid.
Changing concentration of collagen I within the plug will alter the
degree of invasion into the Mini‐Organo, as will the time allowed for
invasion. If the Mini‐Organos are left too long, or the collagen concen-
trations are too low, CCs may invade all the way through the plug. If
collagen concentrations are too high, or invasion times are too short,
then the CCs may only invade a small distance into the Mini‐Organo
or not at all. Altering the extent of initial contraction of the Mini‐
Organos will also alter the extent to which CCs can invade into the
matrix. Typically, 0 CAFs seeded to the Mini‐Organo result in no inva-
sion by CCs, although very low concentrations of collagen or some
highly aggressive CCs (such as the fibrosarcoma line HT1080) may still
invade, and so a 0 CAF control is required to determine the intrinsic
capacity of the tumour cells to invade independently of CAFs.
A pilot experiment to optimise the parameters that lead to approx-
imately 50% invasion into the Mini‐Organo will allow for testing of
inhibitory or stimulatory interventions. In situations where a drug, or
drug(s) of interest may take more than 24 hours to act, or may need
to be given sequentially on separate days, it will be necessary to opti-
mise invasion conditions to yield a slower rate of invasion to accom-
modate for this.3.5 | Scoring and analysis
To determine the extent of invasion of CCs into the Mini‐Organos,
they need to be fixed and processed for histological and immunohisto-
chemical analysis. A wide range of readouts including invasion, prolif-
eration, survival, or differentiation can be conducted (see Figure 3).
i. Triplicates of Mini‐Organo conditions are cut using a scalpel to
generate a flat edge (approximately one‐third of the plug is
removed) and placed side‐by‐side in a cassette and fixed in
10% buffered formalin or 4% paraformaldehyde plus 0.25% glu-
taraldehyde in PBS overnight, followed by transfer to 70%
ethanol.
ii. Once fixed, triplicate Mini‐Organos are processed and paraffin
embedded flat edge down, so that when sectioned, a lateral plane
through the entire Mini‐Organo is generated to provide a com-
plete section of the Mini‐Organo.
iii. Section the Mini‐Organos at 4 to 5 μm using a standard micro-
tome. Three sections per plug, spaced >100 μm apart should be
scored to generate an accurate invasive index.
iv. The choice of staining of the sections will depend on the ques-
tion at hand. Mini‐Organo sections can be stained with
haemotoxylin and eosin (H&E) for visualising and scoring invasion
(examples shown in Figure 3B and 3D‐3F). For some cell lines,
specific markers can also be used such as pan‐cytokeratin
(Figure 3C,G) to distinguish epithelial CCs from stromal CAFs.This may be particularly useful when using large numbers of
CAFs per plug, and in particular where automated cell counting
is being carried out. Additional makers such as Ki67 for prolifer-
ation, or cleaved‐caspase‐3 for apoptosis can also be used to
monitor drug response of CCs that have invaded into the Mini‐
Organos (Figure 3H,I).
v. Once stained, the whole Mini‐Organo should be imaged using
either a slide scanner or tiling microscope at >20× magnification.
It is recommended that scoring of the entire plug be undertaken
rather than randomly chosen ROIs for an accurate quantification
of invasive index. Given the smaller size of Mini‐Organos, analy-
sis of the whole plug is readily achievable. However, care should
be taken when scoring the very outer vertical edges of the gel
where migration down the surface of the gel may have occurred.
When classifying whether a cell has invaded, only include cells
which have entered into the surface of the Mini‐Organo and
travelled at least 25 μm from the plug surface. For accurate scor-
ing, plugs should be fixed and scored whilst cells are still invading
rather than left for longer at which point they may have invaded
all the way through.
vi. Analysis of cell number can be done in a number of ways using
automated image analysis software, for example QuPath66 (Fig-
ures 1I and 3A) or FIJI.67 Depending on the software being used,
two counting areas are outlined. The first is drawn to include all
CCs within the Mini‐Organo. The upper boundary of this area is
drawn approximately 25 μm from the plug surface to which
CCs were seeded. The second counting area is drawn to exclude
CCs still on top of the Mini‐Organo that have not invaded in. Fol-
lowing this, the cell detection is programmed to automatically
count the cells that are within the Mini‐Organo. The automation
of cell counting is advantageous in highly invasive cells lines as
this enables rapid segmentation and identification of cells to
determine invasive index in a time‐efficient manner.
vii. Cell segmentation settings will be dependent on the intensity of
the stain being used, the magnification of the image, and the
software of choice. These should be optimised on a series of pilot
Mini‐Organos prior to any unsupervised analysis.
viii. In order to determine the invasive index, a score is calculated as
the number of cells detected within the whole Mini‐organo sec-
tion divided by the total number of CCs seeded (Figure 3A). An
alternative and often‐used metric is to calculate the invasive
index between the noninvaded upper layer of cells (on top of
the gel) and the total number of invaded cells. Finally, a third
approach is to calculate the area of the “noninvasive” cell layer
(on top) and the “invasive area” (from the top layer down to the
leading edge of the invasive cells), and normalise the invasive
area with total area (noninvasive + invasive).48
Note: All slides should be stained simultaneously for comparison at
the same time to avoid adjusting software parameters for each slide.
Automated nucleus detection parameters are also dependent on
magnification.
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The invasion of CCs into the remodelled collagen plugs can be deter-
mined by H&E staining (Figure 3B and 3D‐3F) or using a cell specific
immunohistochemistry stain for a specific subset, or all CCs using
markers such as pan‐cytokeratin (Figure 3C,G) as we have done previ-
ously.10,58 Various elements can be changed to determine the effects
on CC invasion. For example, standard growth serum (FBS) should
drive the invasion of most CCs. Altering FBS levels may affect invasion
of some CC lines. In our example, we see that the aggressive KPC CCs
invade independent of FBS concentration (Figure 3D). Treatment of
invaded CCs with various anticancer therapies is facilitated and allows
for screening of difference combinations. Here, we show the effects
of Blebbistatin on KPC CC invasion (Figure 3G) and gemcitabine, the
standard‐of‐care therapy for pancreatic cancer on invaded KPC CC
viability. Readouts include measurement of proliferation (Ki67 stain-
ing) (Figure 3H) and apoptosis (CC3) (Figure 3I) using our previously
published staining protocols.10,584 | PRACTICAL APPLICATIONS OF THE
MINI‐ORGANO IN CANCER BIOLOGY
The traditional organotypic contraction assays previously
described10,42 typically take 8 to 12 days to contract, and another
10 to 14 days for invasion. The Mini‐Organo has been optimised to
significantly reduce the equivalent time needed, requiring only
72 hours for contraction and 24 hours for invasion representing an
80% reduction in time required. The Mini‐Organo allows for the same
analysis of the extent and degree of ECM (collagen I) remodelling and
organisation using both standard histological approaches such as
Picrosirus red staining (Figure 2F,G) and SHG imaging for fibrillar col-
lagen (Figure 2G,H). Here we have shown the application of Picrosirius
Red staining, SHG imaging, orientation and alignment analysis,10,60
and grey level co‐occurrence matrix (GLCM) analysis10,58 as examples
of a few of the approaches that can be applied (Figure 2F‐2H).
The contractile phase of the Mini‐Organo allows for the rapid con-
trolled testing of interventions on fibroblast/CAF ability to remodel a
collagen I rich ECM (see Figure 4). Because collagen I represents the
major interstitial ECM component of most tissues, including many
solid tumours, the Mini‐Organo offers a physiologically relevant and
powerful approach to assessing potential stromal cell targeting in the
cancer context. Targeting ECM remodelling as an approach to treat
solid tumours is an exciting emerging concept that is showing promise
in several settings.3,22,25,41,58,684.1 | Targeting and assessing stromal driven collagen
remodelling
Not all CAFs should be considered equal. To highlight this, we have
taken CAFs derived from two matched genetically engineered mouse
models, the tumourigenic and highly invasive KPC (KPC‐CAFs), and
tumourigeneic but poorly invasive KPflC (KPCfl‐CAFs) model ofPDAC. CAFs isolated from these two models show differences in their
ability to remodel the Mini‐Organos reflecting the differing aggres-
siveness of these two GEM models (Figure 4A). To further demon-
strate the potential of testing antistromal cell drugs in the Mini‐
Organo, we demonstrate the effects of three well‐known
anticontractile agents: the nonmuscle Myosin II inhibitor Blebbistatin,
the potent Rho‐associated coiled coil forming protein
serine/threonine kinase (ROCK) inhibitor Fasudil58, and the competi-
tive inhibitor of prolyl hydroxylase domain‐containing proteins
(PHDs); DMOG on the KPC (murine pancreatic cancer CAFs)
(Figure 4B‐4C, quantification of SHG‐GLCM analysis of blebbistatin
treated Mini‐Organos also shown as example in Figure 2H). The addi-
tion of anticontractile drugs leads to a significant reduction in the con-
traction of the Mini‐Organos (Figure 4C) in a dose‐dependent manner
(Figure 4B).
In addition, we evaluated the effects of two YAP/TAZ inhibitors,
Mevastatin and Verteporfin, as well as the actomyosin inhibitor
Blebbistatin, and a second highly potent selective ROCK inhibitor, Y‐
27632 in 3 human patient‐derived CAF cell lines from head and neck
cancer (HN‐CAF), vulval cancer (V‐CAF), and cervical cancer (Cer‐
CAF).48-51 Our data show that HN‐CAFs and V‐CAFs respond to
YAP/TAZ, actomyosin, and ROCK inhibitors in the same manner.
Interestingly, Cer‐CAFs respond to YAP/TAZ inhibitors similar to
HN‐CAFs and V‐CAFS; however, they show no response to the acto-
myosin inhibitor Blebbistatin and the ROCK inhibitor Y‐27632
(Figure 4D‐4F). This data highlight how not all CAFs should be consid-
ered equal and reinforces the notion that cancer coculture studies
should ideally be paired with suitable matching fibroblast/CAF lines
that are relevant to the cancer type being studied, in order to maxi-
mise the fidelity of experimental systems.
CAFs are present at all stages of cancer and are believed to be the
main cell type responsible for regulating the desmoplastic reaction in
cancer. Dissecting the mechanisms underlying CAF activation has
received much attention in the last decade.37,69 As such, CAFs are
believed to be promising targets in cancer. Here, we use our 3D
Mini‐Organo to demonstrate that it is an excellent tool to explore
the mechanisms behind CAF activation.
Transforming growth factor (TGFβ) is the most potent fibrogenic
cytokine known,70-73 and it is now well‐recognised that TGF‐β1 plays
an important role in fibroblast activation, proliferation, and fibrotic
ECM remodelling. In cancer, sustained CAF activation is partly main-
tained through autocrine secretion and stimulation of TGF‐β1 and
SDF‐1α. As expected, exogenously added TGF‐β1 induces CAF activa-
tion and gel contraction of two distinct types of human CAFs (Figure 4
G). Recent work has also demonstrated that prolonged exposure to
hypoxia reduces CAF activation and ECM remodelling.51 We con-
firmed this finding in our model system (Figure 4H,I) and further show
that hypoxic suppression of CAFs can be rescued by the addition of
exogenous TGF‐β1 (Figure 4H,I). These simple 3D experiments dem-
onstrate that the Mini‐Organo is a time‐efficient and physiologically
relevant model system that can be used not only in drug screens,
but also in dissecting molecular mechanisms regulating CAF activation
and ECM remodelling and tumour progression.
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Here, we present a method for the rapid and scalable production of
3D physiologically relevant coculture assays suitable for dissecting
both stromal remodelling and CC invasion. One of the major goals in
designing 3D physiologically relevant in vitro approaches is to capture
the complexity of intercellular communication, nutrient and oxygen
gradients, as well as cell polarity and interactions with the ECM that
is lacking in more traditional 2D monolayer cultures. The Mini‐Organo
offers a simple, straightforward, scalable, and cost‐effective way of
doing this.
Given the enormous number of new anticancer drugs and the
accompanying exponentially increasing number of possible drug com-
binations, the use of in vivo models is prohibitively expensive. There-
fore, approaches such as the “Mini‐Organo” offer a bridge between the
two that allows for higher throughput screening of molecules and
interventions within the standard laboratory environment for imple-
mentation into the clinic, not only in the cancer field but also many
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